Staged Bilateral Exablate Treatment of Medication Refractory Essential Tremor

The objective of this prospective, multi-site, single-arm, open-label study is to capture the safety and efficacy (outcome) of bilateral staged Exablate treatment in subjects with bilateral medication-refractory essential tremor (ET). The staged second procedure will be performed at least 9 months after the first side. The benefit of real-time feedback will allow the physician to maximize benefit without jeopardizing safety. This study is designed as a prospective, open-label, single arm, multi-site study design.